Project Grant HT94252310837
Award Date
8/15/23
Completion Date
8/14/27
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
The Defense Health Agency has awarded a $178,000 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct research on "DISSECTING THE DIFFERENCE IN THE PATHOGENESIS AND IMMUNE MICROENVIRONMENT OF PEDIATRIC AND ADULT OSTEOSARCOMA". This research project falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for the U.S. military and the public. DFCI, a non-profit hospital and cancer...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
Under the $534,000.00 Project Grant awarded by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420), the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) will conduct research to define the role of the androgen receptor in BRCA1/2-deficient prostate cancer. This translational research aims to improve understanding of disease dependencies and develop new treatment approaches for this challenging cancer type. DFCI, a non-profit hospital...
This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $1,598,801.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a Phase 1B study on the BCL-XL degrader DT2216 combined with paclitaxel in recurrent platinum-resistant ovarian cancer. The study, which will take place from July 1, 2025 to June 30, 2029, aims to evaluate the safety and efficacy of this novel treatment approach for a difficult-to-treat form of...
This federal Project Grant award, totaling $4,991,950.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding the "INVESTIGATION OF A MULTICANCER EARLY DETECTION TEST IN A HIGH-RISK MILITARY POPULATION" at the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project aims to develop and evaluate a novel multicancer early detection test for use within a high-risk military...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...